Volker Bornemann, Ph.D. President and CEO Avazyme, Inc. Durham, North Carolina 27703

Sucralose Metabolites Accumulate in Body Fat Over Time

MedicalResearch.com Interview with:

Volker Bornemann, Ph.D. President and CEO Avazyme, Inc. Durham, North Carolina 27703

Dr. Bornemann

Volker Bornemann, Ph.D.
President and CEO
Avazyme, Inc.
Durham, North Carolina 27703

MedicalResearch.com: What is the background for this study?

Response: Since the approval of sucralose in 1998 by the US FDA and by the European Union in 2004, there have been numerous independent reports that suggest sucralose is metabolized in the body and is metabolically active.

These independent studies contradict information submitted to regulatory agencies by sucralose manufacturers who claimed sucralose is safe because it quickly passes through the body unchanged.  In light of these conflicting results, we decided to conduct an experiment to settle the question of whether sucralose is metabolized by the body and determine if it is retained in body fat using the state-of-the art analytic techniques at Avazyme.

MedicalResearch.com: What are the main findings?

Response: The main findings are that sucralose is indeed metabolized in the intestinal tract, and the metabolites are more fat soluble than sucralose itself.  Furthermore, sucralose accumulated in body fat over time.

MedicalResearch.com: What should readers take away from your report?

Response: Sucralose is retained in body fat and is also metabolized contrary to claims by the manufacturer.  A risk assessment of these findings should be performed by regulatory agencies to determine if the metabolites or retention of sucralose in adipose tissue adversely affect human health. 

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: The levels of sucralose and its metabolites in body fat and cell membranes of human consumers of sucralose products should be determined.  In addition, the DNA in fat cells and epithelial cells lining the alimentary tract should be assessed for any adverse changes in DNA.  Further scientific studies should be performed to determine the hazard potential of bioaccumulation of sucralose and the toxicity of the acetylated metabolites. 

Disclosures: This research was supported independently and not by any company associated with the sweetener industry. 

Citation: Volker Bornemann, Stephen C. Werness, Lauren Buslinger & Susan S. Schiffman (2018) Intestinal Metabolism and Bioaccumulation of Sucralose In Adipose Tissue In The Rat, Journal of Toxicology and Environmental Health, Part A, DOI: 10.1080/15287394.2018.1502560

[wysija_form id=”3″]

Sep 1, 2018 @ 10:53 pm

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.